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Abstract
Background Diabetic macular oedema (DMO) is effectively treated with ranibizumab but multiple injections are required.
Where there is also peripheral ischaemia, it has been promoted that targeted panretinal photocoagulation (PRP) may reduce
the number of injections.
Method Patients with optical coherence tomography conﬁrmed DMO and Ultra-wideﬁeld Fundus Fluorescein Angiography
conﬁrmed peripheral retinal ischaemia were randomised to PRP plus ranibizumab or ranibizumab monotherapy. After three
injections, repeat injections were given until the visual acuity was stable and the macula was dry. Re-treatment was given if
there was a drop of visual acuity and/or a recurrence of intra-retinal ﬂuid. The primary outcome was the number of repeat
injections required after the ﬁrst 6 months up until 1 year.
Results There were 49 patients, 25 in the ranibizumab only group and 24 in the ranibizumab+ PRP group recruited at seven
UK sites. The average number of injections in the ranibizumab-only arm was 6.84 over 1 year and 2.52 between months 6
and 12. The average number of injections in the combined arm was 6.67, with the number of injections in the second
6 months 1.92. For the primary outcome, comparing the number of 6- to 12-month injections, the result was not statistically
signiﬁcant (p= 0.33).
Conclusion The addition of targeted PRP to areas of non-perfusion in a patient with DMO does not reduce the number of
injections required in the ﬁrst year. It seems most likely that local VEGF at the macula is the main cause of DMO.
Introduction
Although centre-involving diabetic macular oedema (DMO) is
effectively treated by anti-vascular endothelium growth factor
(VEGF) injections, many patients require a large number of
injections, at least in the ﬁrst year. In the DRCR.net study
(Protocol I) [1], a median of eight injections were required in
the ﬁrst year in the two ranibizumab arms. In the Restore study
[2], a mean of seven injections were given in the ﬁrst year.
These treatments are expensive and cause a signiﬁcant burden
to the patient, their caregivers and the healthcare system.
The exact stimulus for VEGF production in DMO is
unclear. In eyes with DMO and ischaemic peripheral retina
[3], it has been postulated that the VEGF drive may be from
the peripheral retina. Therefore, panretinal photocoagulation
(PRP) targeted to peripheral non-perfused retina may reduce
the VEGF load and in turn reduce the number of anti-VEGF
injections required.
A recently published small trial, the DAVE study [4], did
not ﬁnd a reduction in the number of injections required
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over 3 years. This study evaluated 40 eyes of 29 patients
and performed several sessions of PRP to ensure all the
ischaemic areas of retina were treated. PRP itself can induce
macular oedema and so possibly too much laser counter-
acted the potential beneﬁt. Indeed, in this study there was
less reduction of central retinal thickness (CRT) in the
combined injection/PRP arm compared with monotherapy,
302 µm compared with 152 µm (p= 0.03). The RDP study
used a standard amount of laser targeted to the ischaemic
area of peripheral retina, imaged by Ultra-wideﬁeld Fundus
Fluorescein Angiography (UWFFA), as a one-off treatment
to assess if the number of injections in the second 6 months
of the ﬁrst year of treatment was reduced. The second
6 months was pre-speciﬁed to make allowance for any
possible initial worsening of the DMO due to the laser.
Method
The RDP study was a multicentre UK-based study run
between 2014 and 2017. Patients with optical coherence
tomography (OCT) (Heidelberg Engineering, Heidelberg,
Germany) conﬁrmed centre-involving DMO and UWFFA
(Optomap P200, Optos PLC, Dunfermline, United Kingdom)
conﬁrmed peripheral retinal ischaemia were randomised to
PRP plus ranibizumab or ranibizumab monotherapy.
Prior to any study-related procedures, all patients gave
informed consent. The study had ethics approval (REC
reference 13/NE/0197; IRAS 121940) and was registered
with the clinical trial register (ISRCTN84503751). The
study was performed in line with Good Clinical Practice in
research guidelines and conformed with those of the
Declaration of Helsinki.
The inclusion and exclusion criteria used are shown in
Table 1. Eyes with new vessels were excluded. The
assessment of the OCT scans and fundus ﬂuorecein
angiogram (FFA) was performed by the investigators to
conﬁrm eligibility. The images were subsequently sent to a
reading centre.
Randomisation was by patients rather than eyes, as one
eye per patient was included in the study. Which eye was
chosen, if both were eligible, was at the investigator’s
Table 1 Key inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Visual acuity 20/32 (80 EDTRS letters at 4 m) to 20/320 (30
EDTRS letters 4 m chart)
visual acuity worse than 20/320
Macular oedema secondary to diabetic retinopathy. (OCT
thickness of > 300 µm central subﬁeld, on spectral domain OCT
(Spectralis Heidelberg engineering)
Rubeosis
Peripheral ischaemia seen on UWFFA (20% of the peripheral
retina or more)
Proliferative diabetic retinopathy
Patient able to give consent and take part in all study procedures No recent change to antihypertensive treatment within 2 months of start of
study
BP >180/110 mmHg (if elevated, treatment may be modiﬁed, and patients
may subsequently be considered for recruitment after at least 2 months on
new treatment regime)
Unable to give consent or take part in all study procedures
Other conditions that might interfere with the assessment of the eye such as
cataract or prevent the macular oedema from settling such as vitreomacular
traction, epiretinal membrane, to a degree that would in the opinion of the
investigator affect response to treatment; conditions that would prevent the
visual acuity improving such as foveal atrophy, uveitis
Previous macular laser within 4 months in the study eye
Previous peripheral (PRP) laser in the study eye
Previous injection therapy within last 6 months in the study eye
Pregnant
Uncontrolled systemic illness that in the opinion of the investigator would
preclude involvement
Systemic steroid treatment within 3 months of recruitment, or during the study
Cataract or other intraocular surgery within 3 months
Previous vitrectomy
ETDRS Early Treatment Diabetic Retinopathy Study, OCT optical coherence tomography, UWFFA Ultra-wideﬁeld Fundus Fluorescein
Angiography, BP blood pressure, PRP panretinal photocoagulation
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discretion. Equal numbers of patients were randomised
either to receive or not to receive PRP. Randomisation was
performed via the randomisation service Sealed Envelope.
The ranibizumab treatment criteria were: three injections
28 days apart in all cases ( ± 5 days) then repeat injections
until two stable BCVA measures (within ﬁve LogMAR
letters) and the macula was dry as judged by the investi-
gator. Re-treatment was given if there was a drop of visual
acuity of >5 letters, in the opinion of the investigator due to
a recurrence of DMO, or a recurrence of intra-retinal ﬂuid,
as judged by the examining doctor. All patients were given
three monthly ranibizumab injections and then followed up
at monthly intervals with repeat visual acuity testing and
OCT for a year. Repeat ranibizumab was given based on the
speciﬁed re-treatment criteria.
No macular laser was planned but if the physician felt it
was in the best interests of the patient to have some laser
then it could have been applied but only after 6 months. No
additional PRP was planned unless the patient developed
rubeosis or new vessels that were not controlled by the
injections.
Intervention
The intervention (PRP) arm was given 2000, 200 micro-
metre, laser spots with the Pascal laser (Topcon (GB),
Newbury, United Kingdom), 2 weeks after the ﬁrst ranibi-
zumab injection, to the area of ischaemia seen on UWFFA.
An UWF (Ultra-wideﬁeld) colour and UWFFA was repe-
ated at 1 year.
Comparator
The comparator arm (ranibizumab monotherapy) did not
receive any planned PRP.
Assessments
Best-corrected visual acuity (BCVA) was measured at 4m on
a standard Early Treatment Diabetic Retinopathy Study
(ETDRS) chart at every visit. OCT was performed on the
Heidelberg Spectralis OCT Machine looking at the CRT at
every visit. UWFFA was captured on the Optomap P200, using
eye steering to ensure the maximum area of retina was imaged.
Outcome measures
The primary outcome was the number of repeat ranibizu-
mab injections required after the ﬁrst 6 months up until 1-
year post treatment. Secondary outcomes were: the total
number of injections given over 1 year; difference in BCVA
at 1 year; changes in area of retinal ischaemia on UWFFA;
changes in macular thickness (CRT) on OCT.
Statistical analysis and sample size
The statistical methods and sample size calculations to
examine whether the number of repeat injections differed
between the PRP and non-PRP groups was conducted based
on intention to treat. In order to allow time for any effect of
the PRP treatment to become evident, a lag period of
6 months was used; consequently, the number of injections
during the ﬁnal 6 months of the period of observation was
analysed.
The average numbers of repeated injections in the PRP
and non-PRP groups was compared on the basis that, for
any patient the number of injections followed a binomial
distribution with a possible maximum equal to the total
number of monthly visits during the relevant period (i.e., six
during the ﬁnal 6 months of observation). To allow for the
possibility that these numbers were not binomially dis-
tributed, a Mann–Whitney test was also used to test for
differences between groups. If adjustment is required for
other variables (e.g., level of ischaemia), then logistic
regression was additionally performed.
In order to have 90% power to detect a difference
between groups in the mean number of repeat injections
during the ﬁnal 6 months of the 12-month study period,
based on a two-sided test at the 5% level and assuming
mean numbers 2.5 and 4 in the PRP and non-PRP groups,
respectively, then a total of 28 patients would be required.
Alternatively, if the mean numbers were 3 and 4, respec-
tively, then a total of 60 patients would be required. Based
on this, we opted for a target of 50 patients.
Reading centre methodology for measuring retinal
ischaemia
The UWFFAs were read retrospectively. The images were
sent to the Central Angiographic Resource Facility (CARF),
Institute of Clinical Science, Queens University, Belfast and
graded for degree of retinopathy and area of ischaemia at
baseline and 1 year.
The method for measuring the area of ischaemia and
change in ischaemia involved placing a designed grid
centred on the foveal centre with the following zones:
Foveal zone: diameter of 1.8 mm (= 1DD); Macular zone:
diameter of 7.2 mm (foveal circle is centralised within this
area); Zone 1: diameter of 16.2 mm; Zone 2: diameter of
25.2 mm; Zone 3: diameter of 35.0 mm. This was applied to
the UWFFA images using automated software that cali-
brated the grid to the size of the image being graded, after
the foveal centre was manually marked by the grader. The
area beyond zone 3 was disregarded as it was found to be
incomplete or ungradable in a majority of images (Fig. 1).
Ischaemia was graded in the macular zone and zones 1–3.
Each zone outside the macula was divided into four
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sectors—superior, inferior, temporal, and nasal as shown in
Fig. 1. Within the macula and each of the 12 sectors, the
total area of capillary non-perfusion (CNP) was estimated
by an experienced grader and one of the following ﬁve
grades assigned: no CNP, 1–25%, 26–50%, 51–75%, 76–
100%. CNP was deﬁned as an area of the capillary network
that fails to ﬁll with ﬂuorescein by the late arteriovenous
phase, with minimum linear dimension (MLD) ≥ 63 µm. If
> 50% area of a sector was ungradable, then the grade
‘Cannot grade’ was assigned.
A ﬁnal percentage CNP grade for total retinal non-
perfusion was given for the gradable part of the retina by
considering the individual grades for all the different zones
graded. Areas with PRP laser could not be graded satis-
factorily and therefore it was decided to not assign any
scores to them. At year 1, images were graded in a similar
manner and if new CNP was detected or an increase in CNP
was found, this was stated and the retinal quadrant in which
this was seen was asked to be speciﬁed.
Results
There were 49 patients recruited from 7 centres, 25 in the
ranibizumab only group and 24 in the ranibizumab+ PRP
group. Eighty-seven percent completed 1-year follow-up.
Three patients in the ranibizumab-only arm did not com-
plete the study, one did not want to remain under follow-up
and two died. Three did not complete in the combined arm,
two did not want to remain under follow-up and one died.
The groups were reasonably balanced with a mean baseline
age of 63 years, HbA1c of 80 mmol/mol, blood pressure of
143/80 mmHg, OCT CRT of 391 µm, and area of ischaemia
of 44%. The mean baseline visual acuity was better in the
ranibizumab-only arm at 73 ETDRS letters compared with
67 ETDRS letters (Table 2).
Both arms had two patients that had mild new vessels
detected on the baseline FFA by the reading centre. These
patients were also included in the analysis. The average
number of injections in the ranibizumab-only arm was 6.84
and the number between 6 and 12 months was 2.52 (SD
2.24). The average number of injections in the combined
arm was similar at 6.67, with the number of injections in the
second 6 months being 1.92 (SD 2). For the primary out-
come, comparing the number of 6- to 12-month injections,
the result was not statistically signiﬁcant (p= 0.33).
Similarly comparing the total number of injections in
both groups, the differences were not statistically different
(p= 0.84). The total number of injections also did not relate
to the area of ischaemia in either arms or in the arms
combined (p= 0.24).
There was a statistically signiﬁcant improvement in
visual acuity in each arm, with an average starting BCVA in
the ranibizumab-only arm of 73.7 ETDRS letters improving
to BCVA 77.8 letters (+ 4 letters) and in the combined arm
from BCVA 67.3 letters to BCVA 70.8 letters (+ 3.5).
Allowing for the difference in the baseline BCVA mea-
surements, there was no difference in the mean change in
the visual acuity between the arms although 84% (21/25)
gained vision in the ranibizumab-only arm and only 16/24
(66%) in the combined arm, using last observation carried
forward for the three in each arm without ﬁnal data. This
difference was also not signiﬁcant (p= 0.99). Two patients
lost >10 letters in the ranibizumab arm only and none in the
combined arm. One of these still had very good vision,
having started at 95 letters, which dropped to 82. This may
have been due to the development of some cataract. The
macular oedema had dried up and the retinopathy grade of
severe non proliferative diabetic retinopathy (NPDR) was
the same at the end of the year. In the second case, the
vision dropped from 75 letters to 56. The retinopathy
grading remained as severe NPDR. The image quality at the
end was worse consistent with cataract development,
although there was persistent macular oedema. In the
ranibizumab-only arm, 21/25 also had a ﬁnal visual acuity
of over 72 letters compared with 11/24 in the combined
arm, although the starting vision was lower in this group.
There was a statistically signiﬁcant improvement in the
area of retinal ischaemia in the ranibizumab-only arm (p=
0.0045) compared with baseline but not in the combined
arm (p= 0.29). Ten improved and one became more
ischaemic in the ranibizumab arm despite 10 injections in
the patient who became worse. In the combined arm, seven
improved and four became more ischaemic, the rest having
the same area of ischaemia (Table 3; Figs. 2a, b).
The OCT thickness decreased by a similar amount in
both groups—in the ranibizumab-only arm from 378 µm to
318 µm and in the combined from 405 µm to 310 µm
(Fig. 3).
Fig. 1 Grid designed and placed on the foveal centre, to measure the
area of and change in ischaemia
Randomised trial of wide-ﬁeld guided PRP for diabetic macular oedema treated with ranibizumab 933
No signiﬁcant difference was found in either group when
comparing the following: OCT thickness at baseline and the
area of ischaemia (ranibizumab arm p= 0.72, combined arm
p= 0.17); reduction of OCT thickness at year 1 and the area
of ischaemia (ranibizumab arm p= 0.15, combined arm p=
0.32); total number of injections and initial ischaemia
(ranibizumab arm p= 0.65, combined arm p= 0.28); total
number of injections and improvement in ischaemia (rani-
bizumab arm p= 0.79, combined arm p= 0.98).
Looking at the OCT thickness at baseline of all the
patients (n= 49), there was no statistically signiﬁcant dif-
ference when compared with the initial area of retinal
ischaemia (p= 0.17). The speed of reduction of the OCT
thickness did not vary between the two arms (Fig. 3).
In the ranibizumab arm, FFA at 1 year found an addi-
tional two patients had developed new vessels and an
additional three patients in the combined arm. No additional
laser had been required during the study. No patients had
any serious ocular adverse events, in particular no
endophthalmitis, although two patients lost >10 letters of
vision. Nineteen serious adverse events (SAEs) were
reported, requiring hospital admission, evenly distributed
between the two groups, including three deaths. The deaths
were related to heart disease and the other SAEs were lar-
gely related to complications of diabetes including kidney
disease.
Discussion
Trials using anti-VEGF therapy show that a high number of
treatments are required [1, 2]. In the DRCR.net study Pro-
tocol I [1], only a total of 17 eyes (9%) in the ranibizumab
+ prompt laser group and 15 eyes (8%) in the ranibizumab
+ deferred laser group met ‘success’ criteria at 16 weeks
and did not receive an additional injection before the 1-year
primary outcome visit. In the RDP study, the addition of
peripheral laser did not reduce the number of injections in
total or in the second 6 months. More patients gained vision
in the ranibizumab-only arm although a signiﬁcant differ-
ence in the mean vision change was not observed. The mean
Table 2 Patient demographics
Ranibizumab only Ranibizumab+PRP Total p-Values
No. of eyes 25 24 49 N/A
No. of patients 25 24 49 N/A
Right eye % (no/total) 64% (19/25) 50% (12/24) 63% (31/49) N/A
Age (years), mean (range) 62.64 (40–84) 64.91 (48–83) 63.73 (40–84) 0.4082
Women % (no/total) 16% (4/25) 25% (6/24) 20.41% (10/49) N/A
HbA1c mean (range) 77.78 (45–113) 82.20 (55–111) 80.11 (45–113) 0.6464
BP (mmHg) (average) 138/80 148/81 143/80 0.1553/
0.7778
PDR % (no/total) 8% (2/25) 8.33% (2/24) 8.16% (4/49) N/A
Beginning BCVA mean
(range)
73.68 (48–95) 67.29 (52–89) 70.55 (48–95) 0.0229
Ending BCVA mean (range) 77.88 (56–92) 70.79 (52–89) 74.41 (52–92) 0.0177
Beginning CRT (µm) mean,
(range)
378.36 (308–532) 405.67 (301–1023) 391.74 (301–
1023)
0.4704
Ending CRT (µm) mean,
(range)
316 (224-427) 310.79 (180–541) 313.45 (180–
541)
0.7346
Beginning ischaemia (%)
mean, (range)
43% (25–75%) 45.45% (0–100%) 44.15% (0–
100%)
0.8621
Ending ischaemia (%) mean,
(range)
29.55% (0–50%) 39.47% (0–75%) 34.15% (0–75%) 0.2301
BCVA best-corrected visual acuity, BP blood pressure, CRT central retinal subﬁeld thickness,
ETDRS Early Treatment Diabetic Retinopathy Study, HbA1c glycated haemoglobin, PDR proliferative
diabetic retinopathy
Table 3 Comparing the grade of retinopathy and proportion of
ischaemia in both groups
Ranibizumab (n = 25) Ranibizumab + PRP
(n = 24)
Grade of
retinopathy
Proportion
of ischaemia
Grade of
retinopathy
Proportion
of ischaemia
No change 18 11 16 9
Improvement 3 10 3 7
Worsening 4 1 4 4
Unknown 0 3 1 4
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number of ETDRS letters gained in either arm was less than
expected compared with other studies, however, the starting
vision was higher and the OCT thickness lower. In the
DAVE study [4], there was also a suggestion that the vision
improvement was not as good in the combined arm. The
number of injections given in the RDP was a little lower
than might have been expected in both arms, at 6.7 com-
pared with the median number of 8 injections in the two
arms of the DRCR.net Protocol I study, although similar to
the mean number of 7 used in the Restore study.
There was some improvement in the overall area of
retina measured as perfused in the ranibizumab arm but not
Fig. 2 a Ranibizumab and laser
arm: white arrows showing the
areas of change and re-perfusion
in the month 12 image compared
with baseline. (Images chosen at
the closest time point in FFA
run). b Ranibizumab arm: white
arrows showing the areas of
change and re-perfusion in the
month 12 image compared with
baseline. (Images chosen at the
closest time point in FFA run)
414
350
331
316 319
305 308
310
306
299 302
302
378
338
333
314 315
308 308 310 305 302 305 316
275
300
325
350
375
400
425
2 3 4 5 6 7 8 9 10 11 12
O
CT
 T
hi
ck
ne
ss
 (u
m
)
Study visit number
Changes in OCT thickness from baseline
Ranibizumab + PRP Ranbizimub
Fig. 3 Changes in optical
coherence tomography (OCT)
thickness from baseline in both
the study arms
Randomised trial of wide-ﬁeld guided PRP for diabetic macular oedema treated with ranibizumab 935
in the combined arm. This may not be a fair comparison as
the area of retina measured varied as it was not possible to
make a clear judgement of perfusion in the areas lasered.
Judging changes in areas of perfusion can also be difﬁcult.
It maybe that optocal coherence tomography angiography
(OCTA) would be better for this but this was not done and
currently technology limits the retinal ﬁeld that can be
imaged with OCTA. Neither ranibizumab monotherapy nor
the addition of laser prevented the development of new
vessels completely. The hypothesis was that treating the
non-perfused area of the peripheral retina would reduce the
amount of VEGF and so lead to reduced anti-VEGF ther-
apy. Ultra wideﬁeld FFA (UWF-FFA) has been shown to
better demonstrate the full extent of diabetic retinopathy
compared with seven-ﬁeld imaging [5] but the association
of peripheral retinal non-perfusion with diabetic maculo-
pathy is not clear. Sim et al. [6] found an association of
peripheral retinal ischaemia with an enlarged foveal avas-
cular zone but not macular oedema, whereas a study by
Wessel showed a correlation [3].
In a study of 148 eyes from 76 patients, before the advent
of anti-VEGF injections, using UWF-FFA to measure the
area of non-perfusion, eyes with larger areas of retinal non-
perfusion and worse diabetic retinopathy needed more
macular laser [7].
In a study of 99 eyes being treated for DMO with rani-
bizumab, 49% were associated with microaneurysms, 37%
with peripheral ischaemia and 15% with neovascularisation.
The oedema associated with peripheral ischaemia was more
likely to have a diffuse as opposed to focal pattern and there
was a positive correlation of response to the ischaemic
index. Whether treating this ischaemia would reduce the
recurrence rate was not addressed [8].
Two trials combining UWFFA targeted laser with anti-
VEGF treatments suggested that this combination was
effective, however, they only had 6 months follow-up and
other variables make the conclusions uncertain [9, 10]. The
RaScaL trial [10] studied 30 eyes of 22 patients randomised
to a combination therapy of ranibizumab plus UWFFA-
guided laser compared with a control group that received
combination therapy of intravitreal triamcinolone plus focal
macular laser. Fewer patients in the ranibizumab plus laser
arm needed re-treatment. Takamura et al. [9] randomised 52
patients to bevacizumab or bevacizumab plus targeted PRP
then gave all patients focal laser 2 weeks later and mon-
itored the increase in CRT. In the group with the additional
targeted PRP they found less increase, and this also related
to the area of non-perfusion. Two-thirds of eyes already had
already received standard PRP at baseline.
The Relate study [11] and a small study by Spaide [12]
found that the addition of PRP to ranibizumab injections for
macular oedema due to central retinal vein occlusion did not
show a beneﬁt.
In an analysis of the baseline images of the DAVE study
[13] involving 40 eyes of 29 patients, randomised to anti-
VEGF with or without laser to peripheral ischaemia, the non-
perfused area and total retinal area visible was used to
calculate an ischaemic index in different retinal zones and
correlated to the severity of DMO. The ischaemic index
increased with increasing distance from the fovea but the
severity of the oedema did not correlate with the overall non-
perfused area or ischaemic index [13]. A measure of overall
leakage may better relate to VEGF levels but quantifying leak
from FFA photographs is difﬁcult as the brightness of an
image varies along the run depending on the light exposure.
In the RDP study, one PRP laser of 2000 shots, using the
PASCAL laser, was applied to the ischaemic area found on
UWF-FFA. This amount was chosen as it was felt it would
give some consistency between investigators, would not be
too small an amount to have an effect but would be unlikely
to risk visual ﬁeld loss for what was an unproven treatment.
This might have limited the beneﬁt of the laser, as the amount
could have been varied depending on the amount of ischae-
mia, however, in the DAVE study [4], heavier titrated laser
was applied and repeated during the course of the study. Both
approaches did not show an effect. Both studies are small but
do not suggest that the addition of laser to ranibizumab
monotherapy is beneﬁcial or more precisely the addition of
PRP is not more efﬁcient at reducing VEGF levels than anti-
VEGF alone. Laser may in fact reduce the visual acuity gains
that is achieved with ranibizumab monotherapy. This might
be because PRP does not reduce the VEGF levels enough in
the vitreous to affect the macula and that the non-perfused
area on the FFA is not the only source of cytokines, which
promote the development of macular oedema.
Putting the two studies together, it seems most likely that
posteriorly produced VEGF or local intra-retinal VEGF and
other cytokines at the macula are the main cause of macular
oedema.
Summary
What was known before
● Ranibzumab works well for diabetic macular oedema
(DMO) but many injections are needed in the ﬁrst year.
● Ischaemic retina produces VEGF and blocking VEGF
reduces macular oedema.
● PRP can reduce VEGF levels.
What this study adds
● The addition of PRP to ranibizumab treatment for DMO
does not reduce the number of injections required in the
ﬁrst year of ranibizumab therapy.
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